

DAFTAR PUSTAKA

- Adriaty, D., Prakoeswa, C., Wahyuni, Agusni, I., & Izumi, S. (2020). Leprosy transmission in endemic and non-endemic areas based on the profile of antibody response of PGL-1 and PCR detection of *Mycobacterium leprae*DNA from nasal swab among healthy children of East Java, Indonesia. *Infectious Disease Reports*, 12, 8543. <https://doi.org/10.4081/idr.2020>
- Arsyad, Y., Jifanti, F., Amiruddin, M. D., Anwar, A. I., Adriati, D., Wahyuni, R., Iswahyudi, Agusni, I., & Izumi, S. (2012). Comparative Study on the Intensity of *Mycobacterium leprae* Exposure Between Household and Non-Household Kontak of Leprosy. *Indonesian Journal of Tropical and Infectious Disease*, 3(1), 1–4.
- Beissner, M., Woestemeier, A., Saar, M., Badziklou, K., Maman, I., Amedifou, C., Wagner, M., Wiedemann, F. X., Amekuse, K., Kobara, B., Herbinger, K., Kere, A. B., Löscher, T., & Bretzel, G. (2019). Development of a combined RLEP / 16S rRNA (RT) qPCR assay for the detection of viable *M. leprae* from nasal swab samples. *BMC Infectious Diseases*, 19, 1–10.
- Bhat, R. M., & Prakash, C. (2012). Leprosy: An Overview of Pathophysiology. *Interdisciplinary Perspectives on Infectious Diseases*, 2012, 1–6. <https://doi.org/10.1155/2012/181089>
- Brennan, P. J., & Spencer, J. S. (2019). The Physiology of *Mycobacterium leprae* Morphology and Cell Wall. In *The International Textbook of leprosy* (Issue 6, pp. 1–51).
- Calado, K. L. S., Magnanini, M. M. F., Moura, R. S. de, Gallo, M. E. N., Bührer-Sékula, S., & Oliveira, M. L. W.-D.-R. de. (2013). Serology with ML Flow test in health professionals from three different states of Brazil. *Anais Brasileiros de Dermatologia*, 88(6), 918–923. <https://doi.org/10.1590/abd1806-4841.20132139>
- Chou, R., & Poobalan, A. (2018). *Guidelines for the Diagnosis, Treatment and Prevention of Leprosy*. World Health Organization.
- Cole, S. T., Eglmeier, K., Parkhill, J., James, K. D., Thomson, N. R., Wheeler, P. R., Honoré, N., Garnier, T., Churcher, C., Harris, D., Mungall, K., Basham, D., Brown, D., Chillingworth, T., Connor, R., Davies, R. M., Devlin, K., Duthoy, S., Feltwell, T., ... Barrell, B. G. (2001). Massive gene decay in the leprosy bacillus. *Nature*, 409(6823), 1007–1011. <https://doi.org/10.1038/35059006>
- Darmaputra, I. G. N., & Ganeswari, P. A. D. (2018). Peran sitokin dalam kerusakan saraf pada penyakit kusta: Tinjauan Pustaka. *Intisari Sains Medis*, 9(3), 92–100. <https://doi.org/10.15562/ism.v9i3.328>
- Eichelmann, K., & González, S. E. G. (2013). Leprosy . An Update : Definition , Pathogenesis , Classification , Diagnosis , and Treatment &. *Actas Dermosifiliograficas*, 104(7), 554–563.
- Feeenstra, S. G., Nahar, Q., Pahan, D., Oskam, L., & Richardus, J. H. (2013). Social Kontak patterns and leprosy disease: A case-control study in

- Bangladesh. *Epidemiology and Infection*, 141(3), 573–581. <https://doi.org/10.1017/S0950268812000969>
- Fontes, A. N. B., Gomes, H. M., de Araujo, M. I., de Albuquerque, E. C. A., Baptista, I. M. F. D., Moura, M. M. da F., Rezende, D. S., Pessolani, M. C. V., Lara, F. A., Pontes, M. A. de A., Gonçalves, H. de S., Lucena-Silva, N., Sarno, E. N., Vissa, V. D., Brennan, P. J., & Suffys, P. N. (2012). Genotyping of *Mycobacterium leprae* present on Ziehl-Neelsen-stained microscopic slides and in skin biopsy samples from leprosy Pasiens in different geographic regions of Brazil. *Memorias Do Instituto Oswaldo Cruz*, 107(SUPPL.1), 143–149. <https://doi.org/10.1590/S0074-02762012000900021>
- Fontes, A. N. B., Lima, L. N. G. C., Mota, R. M. S., Almeida, R. L. F., Pontes, M. A., Gonçalves, H. de S., Frota, C. C., Vissa, V. D., Brennan, P. J., Guimaraes, R. J. P. S., Kendall, C., Kerr, L. R. F. S., & Suffys, P. N. (2017). Genotyping of *Mycobacterium leprae* for better understanding of leprosy transmission in Fortaleza, Northeastern Brazil. *PLoS Neglected Tropical Diseases*, 11(12), 1–20. <https://doi.org/10.1371/journal.pntd.0006117>
- Gama, R. S., Artur, T., Gomides, R., Fróes, C., Gama, M., Justo, S., Moreira, M., Saloum, F., Manta, D. N., Oliveira, L. B. P. De, Henrique, P., Marçal, F., Sarno, E. N., Moraes, M. O., Marcel, R., Garcia, G., Alves, L., & Fraga, D. O. (2018). High frequency of *M. leprae* DNA detection in asymptomatic household Kontaks. *BMC Infectious Diseases*, 18(153), 1–6.
- Govindharaj, P., Srinivasan, S., & Darlong, J. (2018). Quality of life of persons affected by leprosy in an endemic district, West Bengal, India. *Indian Journal of Dermatology*, 63(6), 459–464.
- Gunawan, H., Fakhrosa, I., Saraswati, N. A., Sasmojo, M., Hindritiani, R., & Suwarsa, O. (2019). Genotyping of *Mycobacterium leprae* in a Son-and-Father Pair of Pasiens Indicated the Possible Mode of Leprosy Transmission: a Case Report. *Serbian Journal of Dermatology and Venereology*, 10(3), 96–100. <https://doi.org/10.2478/sjdv-2018-0014>
- Hadi, Moch. I., & Kumalasari, M. L. F. (2017). *Kusta Stadium Subklinis Faktor Risiko dan Permasalahannya* (1st ed.). UIN Sunan Ampel.
- Hajar, S. (2016). Morbus Hansen. *Jurnal Kedokteran Syiah Kuala*, 17(3), 190–194.
- Job, C. K., Jayakumar, J., Kearney, M., & Gillis, T. P. (2008). Transmission of leprosy: A study of skin and nasal secretions of household Kontaks of leprosy Pasiens using PCR. *American Journal of Tropical Medicine and Hygiene*, 78(3), 518–521.
- Kamal, R., Dayal, R., Gaidhankar, K., Biswas, S., Gupta, S. B., Kumar, N., Kumar, R., Pengoria, R., Chauhan, D. S., Katoch, K., Katoch, V. M., & Singh, P. K. (2016). RLEP PCR as a definitive diagnostic test for leprosy from skin smear samples in childhood and adolescent leprosy. *Indian Journal of Leprosy*, 88(4), 193–197.
- Kemenkes RI. (2018). *Hapuskan Stigma dan Diskriminasi terhadap Kusta*. Pusat Data dan Informasi Kemenkes.

- Kemenkes RI. (2019). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 11 Tahun 2019 Tentang Penanggulangan Kusta*.
- Kemenkes RI. (2020). *Profil Kesehatan Indonesia 2019*. Kemenkes RI. <https://doi.org/10.1017/CBO9781107415324.004>
- Kemenkes RI. (2022). *Profil Kesehatan Indonesia 2021*.
- Lastoria, J. C., & de Abreu, M. A. M. M. (2014). Leprosy: A review of laboratory and therapeutic aspects - Part 2. *Anais Brasileiros de Dermatologia*, 89(3), 389–401. <https://doi.org/10.1590/abd1806-4841.20142460>
- Lastória, J. C., & de Abreu, M. A. M. M. (2014). Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects – Part 1. *Anais Brasileiros de Dermatologia*, 89(2), 205–218.
- Lavania, M., Jadhav, R. S., Turankar, R. P., Chaitanya, V. S., Singh, M., & Sengupta, U. (2013). Single nucleotide polymorphisms typing of *Mycobacterium leprae* reveals focal transmission of leprosy in high endemic regions of India. *Clinical Microbiology and Infection*, 19(11), 1058–1062. <https://doi.org/10.1111/1469-0691.12125>
- Lavania, M., Jadhav, R., Turankar, R. P., Singh, I., Nigam, A., & Sengupta, U. (2015). Genotyping of *Mycobacterium leprae* strains from a region of high endemic leprosy prevalence in India. *Infection, Genetics and Evolution*, 36(September 2018), 256–261. <https://doi.org/10.1016/j.meegid.2015.10.001>
- Martinez, A. N., Talhari, C., Moraes, M. O., & Talhari, S. (2014). PCR-Based Techniques for Leprosy Diagnosis: From the Laboratory to the Clinic. *PLoS Neglected Tropical Diseases*, 8(4), 1–8. <https://doi.org/10.1371/journal.pntd.0002655>
- Matsuoka, M., Zhang, L., Budiawan, T., Saeki, K., & Izumi, S. (2004a). Genotyping of *Mycobacterium leprae* on the Basis of the Polymorphism of TTC Repeats for Analysis of Leprosy Transmission. *Journal of Clinical Microbiology*, 42, 741–745. <https://doi.org/10.1128/JCM.42.2.741-745.2004>
- Matsuoka, M., Zhang, L., Budiawan, T., Saeki, K., & Izumi, S. (2004b). Genotyping of *Mycobacterium leprae* on the Basis of the Polymorphism of TTC Repeats for Analysis of Leprosy Transmission. *Journal of Clinical Microbiology*, 42(2), 741–745. <https://doi.org/10.1128/JCM.42.2.741-745.2004>
- Misch, E. A., Berrington, W. R., Vary, J. C., & Hawn, T. R. (2010). Leprosy and the Human Genome. *Microbiology and Molecular Biology Reviews*, 74(4), 589–620. <https://doi.org/10.1128/mmbr.00025-10>
- Mudatsir, M. (2013). Perkembangan terkini penelitian kusta secara biologi molekuler. *Jurnal Kedokteran Syiah Kuala*, 13(2), 105–109.
- Naik, S. M., More, S. A., & Joshi, S. R. (2022). Correlation of Histomorphological Findings with Bacteriological Index in Leprosy Pasiens. *Iranian Journal of Pathology*, 17(1), 48–55. <https://doi.org/10.30699/IJP.2021.534122.2682>
- Oliveira Medeiros, I. P. De, Deps, P. D., & Antunes, de P. J. M. A. (2019). Armadillos and leprosy: from infection to biological model. *Journal of the Sao Paulo Institute of Tropical Medicine*, 61, 1–7.

- Partogi, D., Dalimunthe, D. A., & Hazlianda, C. P. (2018). A Study of Selenium in Leprosy. *Open Access Macedonian Journal of Medical Sciences*, 6(3), 485–487. <https://doi.org/10.3889/oamjms.2018.136>
- Patrocínio, L. G., Goulart, I. M. B., Goulart, L. R., Patrocínio, J. A., Ferreira, F. R., & Fleury, R. N. (2005). Detection of *Mycobacterium leprae* in nasal mucosa biopsies by the polymerase chain reaction. *FEMS Immunology and Medical Microbiology*, 44(3), 311–316. <https://doi.org/10.1016/j.femsim.2005.01.002>
- Pinheiro, R. O., Salles, J., Sarno, E., & Sampaio, E. (2011). *Mycobacterium leprae*–host-cell interactions and genet. *Future Microbiol*, 6(2), 217–230. <https://doi.org/10.2217/fmb.10.173>. *Mycobacterium*
- Pinheiro, R. O., Schmitz, V., de Andrade Silva, B. J., Dias, A. A., de Souza, B. J., de Mattos Barbosa, M. G., de Almeida Esquenazi, D., Pessolani, M. C. V., & Sarno, E. N. (2018). Innate immune responses in leprosy. *Frontiers in Immunology*, 9(MAR), 1–15. <https://doi.org/10.3389/fimmu.2018.00518>
- Ploemacher, T., Faber, W. R., Menke, H., Rutten, V., & Id, T. P. (2020). Reservoirs and transmission routes of leprosy ; A systematic review. *PLoS Neglected Tropical Diseases*, 14(4), 1–27. <https://doi.org/10.1371/journal.pntd.0008276>
- Prakoeswa, F. R. S., & Sutrisna, E. (2017). Leprosy, An Overview of Epidemiology and Risk Factor in Indonesia. *J.Bio.Innov6*, 6(6), 991–995.
- Romero-Montoya, M., Beltran-Alzate, J. C., & Cardona-Castro, N. (2017). Evaluation and Monitoring of *Mycobacterium leprae* Transmission in Household Kontaks of Pasiens with Hansen's Disease in Colombia. *PLoS Neglected Tropical Diseases*, 11(1), 1–11. <https://doi.org/10.1371/journal.pntd.0005325>
- Sato, C. M., Rodrigues, T. da S. V., Silva, P. R. de S., dos Santos, E. S., Xavier, D. R., Baptista, I. M. F. D., Cortela, D. da C. B., Ignotti, E., & Ferreira, S. M. B. (2022). Social school Kontaks of multibacillary leprosy cases in children living in the hyperendemic region of the Midwest of Brazil. *Jornal de Pediatria*, 98(4), 431–437. <https://doi.org/10.1016/j.jped.2021.11.009>
- Scollard, D. M. (2017). Pathogenesis and Pathology of Leprosy. In *The International Textbook of Leprosy* (Issue Figure 1, pp. 1–26).
- Shin, Y. C., Lee, H., Lee, H., Walsh, G. P., Kim, J. D., & Cho, S. N. (2000). Variable numbers of TTC repeats in *Mycobacterium leprae* DNA from leprosy Pasiens and use in strain differentiation. *Journal of Clinical Microbiology*, 38(12), 4535–4538. <https://doi.org/10.1128/jcm.38.12.4535-4538.2000>
- Shin, Y.-C., Lee, H., Lee, H., Walsh, G. P., Kim, J.-D., & Cho, S.-N. (2000). Variable Numbers of TTC Repeats in *Mycobacterium leprae* DNA from Leprosy Pasiens and Use in Strain Differentiation. In *JOURNAL OF CLINICAL MICROBIOLOGY* (Vol. 38, Issue 12).
- Sigit Prakoeswa, C. R., Rumondor, B. B., Damayanti, L., Sasmojo, M., Adriaty, D., Alinda, M. D., Wahyuni, R., Listiawan, M. Y., Agusni, I., & Izumi, S. (2019). Distribution of *Mycobacterium leprae* genotypes from Surabaya and Bandung Clinical Isolates by Multiple Locus Variable Number of Tandem

- Repeat Analysis. *Dermatology Reports*, 11(February).
<https://doi.org/10.4081/dr.2019.8017>
- Singh, R., Singh, B., & Mahato, S. (2019). Community knowledge , attitude , and perceived stigma of leprosy amongst community members living in Dhanusha and Parsa districts of Southern Central Nepal. *PLoS Neglected Tropical Diseases*, 13(1), 1–19.
- Tatipally, S., Srikantam, A., & Kasetty, S. (2018). Polymerase Chain Reaction (PCR) as a Potential Point of Care Laboratory Test for Leprosy Diagnosis—A Systematic Review. *Tropical Medicine and Infectious Disease*, 3(4)Tatipally, S., Srikantam, A., Kasetty, S. (2018). Polymerase Chain Reaction (PCR) as a Potential Point of Care Laboratory Test for Leprosy Diagnosis—A Systematic Review. *Tropical Medicine and Infectious Disease*, 3(4), 107. <https://doi.org/10.3390/tropi>, 107.
<https://doi.org/10.3390/tropicalmed3040107>
- Tió-coma, M., Wijnands, T., Pierneef, L., Schilling, A. K., Alam, K., Roy, J. C., Faber, W. R., Menke, H., Pieters, T., Stevenson, K., Richardus, J. H., & Geluk, A. (2019). Detection of *Mycobacterium leprae* DNA in soil: multiple needles in the haystack. *Scientific Reports*, 9(3165), 1–7.
<https://doi.org/10.1038/s41598-019-39746-6>
- Toh, H. S., Maharjan, J., Thapa, R., Neupane, K. D., Shah, M., Baral, S., Hagge, D. A., Napit, I. B., & Lockwood, D. N. J. (2018). Diagnosis and impact of neuropathic pain in leprosy Pasiens in Nepal after completion of multidrug therapy. *PLoS Neglected Tropical Diseases*, 12(7), 1–15.
<https://doi.org/10.1371/journal.pntd.0006610>
- Turankar, R. P., Lavania, M., Chaitanya, V. S., Sengupta, U., Darlong, J., Darlong, F., Siva Sai, K. S. R., & Jadhav, R. S. (2014). Single nucleotide polymorphism-based molecular typing of *M. leprae* from multicase families of leprosy Pasiens and their surroundings to understand the transmission of leprosy. *Clinical Microbiology and Infection*, 20(3), 142–149.
<https://doi.org/10.1111/1469-0691.12365>
- Turankar, R. P., Lavania, M., Singh, M., Sengupta, U., Sai, K. S. R. S., & Jadhav, R. S. (2016). Presence of viable *Mycobacterium leprae* in environmental specimens around houses of leprosy Pasiens. *Indian Journal of Medical Microbiology*, 34(3), 315–321.
- Turankar, R. P., Lavania, M., Singh, M., Siva Sai, K. S. R., & Jadhav, R. S. (2012). Dynamics of *Mycobacterium leprae* transmission in environmental context: Deciphering the role of environment as a potential reservoir. *Infection, Genetics and Evolution*, 12(1), 121–126.
<https://doi.org/10.1016/j.meegid.2011.10.023>
- Turankar, RP., Pandey, S., Lavania, M., Singh, I., Nigam, A., Darlong, J., Darlong, F., & Sengupta, U. (2015). Comparative evaluation of PCR amplification of RLEP, 16S rRNA, rpoT and Sod A gene targets for detection of *M. leprae* DNA from clinical and environmental samples. *International Journal of Mycobacteriology*, 4(1), 54–59.
<https://doi.org/10.1016/j.ijmyco.2014.11.062>

- Wahyuni, R., Adriaty, D., Prakoeswa, C. R. S., Agusni, I., & Izumi, S. (2010). *Mycobacterium leprae* in Daily Water Resources of Inhabitants Who Live in Leprosy Endemic Area of East Java. *Indonesian Journal of Tropical and Infectious Disease*, 1(2), 65–68.
- Weng, X., Heiden, J. Vander, Xing, Y., Liu, J., & Vissa, V. (2011). Transmission of leprosy in Qiubei County, Yunnan, China: Insights from an 8-year molecular epidemiology investigation. *Infection, Genetics and Evolution*, 11(2), 363–374. <https://doi.org/10.1016/j.meegid.2010.11.014>
- WHO. (2020). *Leprosy/Hansen disease: Kontak tracing and post-exposure prophylaxis, Technical Guidance*. World Health Organization.
- WHO. (2022). *Global leprosy (Hansen disease) update , 2021 : moving towards interruption of transmission Situation*.

LAMPIRAN

LAMPIRAN 1. FOTO KEGIATAN PENELITIAN



Kegiatan Pengambilan Sampel di dan Kota Kendari



Kegiatan Pengambilan Sampel di Kabupaten Muna

LAMPIRAN 2. MASTER TABEL HASIL PENELITIAN

No	ID	Status	RELATION	ID Specimen			Lokasi	Durasi	Index	TTC	TTC	TTC	TTC REPEATED		
	Sampel			Skin	Blood	Nasal		P.obatan	Bakteri	Skin	Nose	Blood	Skin	Nose	Blood
1	P1	Patient 1	MOTHER	S.P1	B.P1	N.P1	Kendari	SELESAI	(+1)	POS	POS	NEG	14	14	
2	H1	Contact 1	SON	S.H1	B.H1	N.H1	Kendari			POS	NEG		12		
3	P2	Patient 2	HUSBAND	S.P2	B.P2	N.P2	Kendari	8 BULAN	(+1)	POS	POS	NEG		14	
4	H2	Contact 2	WIFE	S.H2	B.H2	N.H2	Kendari			POS	NEG		14		
5	P3	Patient 3	DAUGHTER	S.P3	B.P3	N.P3	Kendari	4 BULAN	(+1)	POS	POS	NEG	14	14	
6	H3	Contact 3	SISTER	S.H3	B.H3	N.H3	Kendari			POS	NEG		12		
7	P4	Patient 4	MOTHER	S.P4	B.P4	N.P4	Kendari	4 BULAN	(+1)	NA	POS	NEG		14	
8	P5	Patient 5	DAUGHTER	S.P5	B.P5	N.P5	Kendari	2 BULAN	NEG	POS	POS	NEG	13	13	
9	P6	Patient 6	FATHER	S.P6	B.P6	N.P6	Kendari	1/2 BULAN	(+1)	POS	POS	NEG	14	13	
10	P7	Patient 7	DAUGHTER	S.P7	B.P7	N.P7	Kendari	6 BULAN	(+2)	POS	POS	NEG	13	14	
11	H7	Contact 7	BROTHER	S.H7	B.H7	N.H7	Kendari			POS	NEG		13		
12	P8	Patient 8	WIFE	S.P8	B.P8	N.P8	Kendari	SELESAI	(+1)	POS	POS	NEG	14	13	
13	H8	Contact 8	HUSBAND	S.H8	B.H8	N.H8	Kendari			POS	NEG		14		
14	P9	Patient 9	MOTHER	S.P9	B.P9	N.P9	Kendari	3 BULAN	(+2)	POS	POS	NEG	14	13	
15	P10	Patient 10	MOTHER	S.P10	B.P10	N.P10	Kendari	8 BULAN	(+1)	POS	POS	NEG	12	14	
16	H10	Contact 10	DAUGHTER	S.H10	B.H10	N.H10	Muna			POS	POS		13	13	
17	P11	Patient 11	FATHER	S.P11	B.P11	N.P11	Muna	3 BULAN	NEG	POS	POS	NEG	14	14	
18	H11.1	Contact 11.1	DAUGHTER	NA	B.H11.1	N.H11.1	Muna			POS	NEG		13		
19	H11.2	Contact 11.2	DAUGHTER	NA	B.H11.2	N.H11.2	Muna			POS	NEG		14		
20	H11.3	Contact 11.3	SON IN LAW	NA	B.H11.3	N.H11.3	Muna			POS	NEG		14		
21	H11.4	Contact 11.4	DAUGHTER	NA	B.H11.4	N.H11.4	Muna			POS	NEG		15		
22	P12	Patient 12	HUSBAND	S.P12	B.P12	N.P12	Muna	P. BARU	(+3)	POS	POS	POS	14	15	15
23	H12	Contact 12	WIFE	NA	B.H12	N.H12	Muna			POS	NEG		14		
24	P13	Patient 13	HUSBAND	S.P13	B.P13	N.P13	Muna	SELESAI	NEG	POS	POS	NEG	15	14	
25	H13.1	Contact 13.1	WIFE	NA	B.H13.1	N.H13.1	Muna			POS	NEG		14		
26	H13.2	Contact 13.2	DAUGHTER	NA	B.H13.2	N.H13.2	Muna			POS	NEG		14		
27	H13.3	Contact 13.3	DAUGHTER	NA	B.H13.3	N.H13.3	Muna			POS	NEG		14		
28	H13.4	Contact 13.4	DAUGHTER	NA	B.H13.4	N.H13.4	Muna			POS	NEG		15		
29	H13.5	Contact 13.5	SON	NA	B.H13.5	N.H13.5	Muna			POS	NEG		14		
30	P14	Patient 14	HUSBAND	S.P14	B.P14	N.P14	Muna	SELESAI	(+3)	POS	POS	NEG	28	14	
31	H14.1	Contact 14.1	WIFE	NA	B.H14.1	N.H14.1	Muna			POS	NEG		14		
32	H14.2	Contact 14.2	SON	NA	B.H14.2	N.H14.2	Muna			POS	NEG		15		
33	P15	Patient 15	SON	S.P15	B.P15	N.P15	Muna	3 BULAN	NEG	POS	POS	NEG	27	15	
34	H15.1	Contact 15.1	MOTHER	NA	B.H15.1	N.H15.1	Muna			POS	NEG		14		
35	H15.2	Contact 15.2	BROTHER	NA	B.H15.2	N.H15.2	Muna			POS	NEG		13		
36	P16	Patient 16	HUSBAND	S.P16	B.P16	N.P16	Muna	SELESAI	NEG	POS	POS	NEG	13	14	
37	H16.1	Contact 16.1	WIFE	NA	B.H16.1	N.H16.1	Muna			POS	NEG		14		
38	H16.2	Contact 16.2	DAUGHTER	NA	B.H16.2	N.H16.2	Muna			POS	NEG		14		
39	P17	Patient 17	HUSBAND	S.P17	B.P17	N.P17	Muna	1,5 BULAN	(+3)	POS	POS	POS	13	14	12

40	H17.1	Contact 17.1	WIFE	NA	B.H17.1	N.H17.1	Muna				POS	NEG		14
41	H17.2	Contact 17.2	Mother in Law	NA	B.H17.2	N.H17.2	Muna				POS	NEG		14
42	P18	Patient 18	HUSBAND	NA	B.P18	N.P18	Muna	SELESAI			POS	NEG		15
43	H18.1	Contact 18.1	WIFE	NA	B.H18.1	N.H18.1	Muna				POS	NEG		15
44	H18.2	Contact 18.2	DAUGHTER	NA	B.H18.2	N.H18.2	Muna				POS	NEG		14
45	P19	Pasien 19	SON	NA	B.P19	N.P19	Muna	SELESAI			POS	NEG		14
46	H19.1	Contact 19.1	SISTER	NA	B.H19.1	N.H19.1	Muna				POS	NEG		14
47	H19.2	Contact 19.2	SISTER	NA	B.H19.2	N.H19.2	Muna				POS	NEG		14
48	P20	Patient 20	SON	S.P20	B.P20	N.P20	Muna	SELESAI	(+1)	POS	POS	NEG	22	14
49	H20.1	Contact 20.1	BROTHER	NA	B.H20.1	N.H20.1	Muna				POS	NEG		14
50	H20.2	Contact 20.2	SISTER	NA	B.H20.2	N.H20.2	Muna				POS	NEG		13
51	H20.3	Contact 20.3	SISTER	NA	B.H20.3	N.H20.3	Muna				POS	NEG		14
52	P21	Patient 21	WIFE	S.P21	B.P21	N.P21	Muna	SELESAI	NEG	POS	POS	NEG	14	14
53	H21.1	Contact 21.1	HUSBAND	NA	B.H21.1	N.H21.1	Muna				POS	NEG		14
54	H21.2	Contact 21.2	DAUGHTER	NA	B.H21.2	N.H21.2	Muna				POS	NEG		14

Keterangan:

P=Pasien

H= Household Contact

B= Darah


N= Nasal Swab

S= Skin smear


Pos = positif

Neg = negative


LAMPIRAN 3. HASIL ELEKTROFORESIS PEMERIKSAAN PCR




Gambar 20. Produk PCR sampel Skin Smear. Lane 1 DNA marker (M) 129 bp ladder target gen RLEp X17153 dengan primer Lp1-Lp2 nested Lp3-Lp4; Lane S. P1 sampai S. P10 dan S. P11-S.P21 sampel dengan elektroforesis 2,5%.




Gambar 21a. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 129 bp ladder target gen RLEp X17153 dengan primer Lp1-Lp2 nested Lp3-Lp4; Lane N. P1 sampai N. H10 sampel dengan elektroforesis 2,5%.




Gambar 21b. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 129 bp ladder target gen RLEp X17153 dengan primer Lp1-Lp2 nested Lp3-Lp4; Lane N. P11 sampai N. H14.2 sampel dengan elektroforesis 2,5%.




Gambar 21c. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 129 bp ladder target gen RLEp X17153 dengan primer Lp1-Lp2 nested Lp3-Lp4; Lane P15-H19 sampel dengan elektroforesis 2,5%.




Gambar 21d. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 129 bp ladder target gen RLEp X17153 dengan primer Lp1-Lp2 nested Lp3-Lp4; Lane sampel P20-H21.2 dengan elektroforesis 2,5%.




Gambar 22. Produk PCR sampel darah. Lane 1 DNA marker (M) 129 bp ladder target gen RLEp X17153 dengan primer Lp1-Lp2 nested Lp3-Lp4; Lane 2 Kontrol negatif , lane B1 sampai Lane B54 sampel dengan elektroforesis 2,5%




Gambar 23a. Produk PCR sampel Kulit. Lane 1 DNA marker (M) 200 bp ladder target gen RLEp X17153 dengan primer TTC-A dan TTC-B; lane S.P1 sampai S.P10 dengan elektroforesis 2,5 %.




Gambar 23b. Produk PCR sampel Kulit. Lane 1 DNA marker (M) 200 bp ladder target gen RLEp X17153 dengan primer TTC-A dan TTC-B; lane S.P11 sampai S.P21 dengan elektroforesis 2,5 %.




Gambar 24a. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 200 bp ladder target gen RLEp X17153 dengan primer TTC A-TTC B; Lane N. P1- NH10 sampel dengan elektroforesis 2,5%.




Gambar 23b. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 200 bp ladder target gen RLEp X17153 dengan primer TTC A-TTC B; Lane N. P11-N. H14.2 sampel dengan elektroforesis 2,5%.



Gambar 23c. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 200 bp ladder target gen RLEp X17153 dengan primer TTC A-TTC B; Lane N. P15-NH19.2 sampel dengan elektroforesis 2,5%.



Gambar 23d. Produk PCR sampel Nasal Swab. Lane 1 DNA marker (M) 200 bp ladder target gen RLEp X17153 dengan primer TTC A-TTC B; Lane N. P20- N. H21.2 sampel dengan elektroforesis 2,5%.




Gambar 25. Produk PCR sampel Whole Blood. Lane M (DNA marker 200 bp) ; Lane K- (Kontrol negatif) , lane B1 sampai Lane B54 sampel elektroforesis 2,5 %. Voltage 100 Volt.

LAMPIRAN 4. HASIL PENSEJAJARAN SEKUENSING

A. PRIMER LP

1. MK256209.1 China	TGTTATA-CGGGG-C-AC-GGGGG-CAA-TCCGTGTT-AAGTCGGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
2. OK18877.1 Brazil	GGGGCG-TTTTA-STGT-GGGGA-CGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
3. X17151.1 Indonesia (NTT)	GGGGCG-TTTTA-STGT-GCAAGTCAT-GGGAA-CGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
4. X17153.1 Indonesia (NTT)	GGGGCG-TTTTA-STGT-GCAAGTCAT-GGGAA-CGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
5. OK18877.1 Brazil	GGGGCG-TTTTA-CGGTG-C-AC-GGGGG-CAA-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
6. MF975705.1 Brazil	GGGGCG-TTTTA-CGGTG-C-AC-GGGGG-CAA-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
7. MF975706.1 Brazil	GGGGCG-TTTTA-CGGTG-C-AC-GGGGG-CAA-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
8. SP1	GGGGCG-TTTTA-CGGTG-C-AC-GGGGG-TACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
9. BH1	GGGGCG-TTTTA-ACCGCTG-CGAC-GGGGG-AAAGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
10. BP1	GGGGCG-TTTTA-CGGTG-C-AC-GGGGG-GTAGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
11. BP2	CANGTACCGT-CGAC-GGGG-AACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
12. SP2	-GGTAA-CGGTG-CGAC-GGGG-AACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
13. SH2	GGGGCG-TTTTA-CGGTG-CGAC-GGGG-AAGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
14. BH2	GGGGCG-TTTTA-CGGTG-CGAC-GGGG-AAGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
15. SP3	GGGGCG-TTTTA-CGGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
16. BP3	GGGGCG-TTTTA-CGGTG-CGAC-GGGG-NACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
17. BP4	GGGGCG-TTTTA-CGGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
18. BP6	GGGGCG-TTTTA-ACCGCTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
19. BH7	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-AAAGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
20. SP7	TGTTATA-CGGTG-CGAC-GGGG-AACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
21. SH7	GGGGCG-TTTTA-CGGTG-CGAC-GGGG-TACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
22. BP8	NAAGTATA-CGGTG-CGAC-GGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
23. BH8	NAAGTATA-CGGTG-CGAC-GGGG-AAAGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
24. SH8	NAAGTATA-CGGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
25. BP9	NAAGTATA-CGGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
26. SP9	NAAGTATA-CGGTG-CGAC-GGGGG-TACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
27. SP10	AAAATTA-CGGTG-CGAC-GGGG-AAGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
28. BP10	CAANTATA-CGGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
29. BH10	ATGTAACGCGT-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
30. BH112	CAATTACCGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
31. BH113	CAATTACCGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
32. SP11	TGTTATA-CGGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
33. BH111	NAATATA-CGGTG-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
34. BP11	TAAGTATA-CGGTG-CGAC-GGGGG-TACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
35. SP12	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
36. BP12	ATGTAACGCGT-CGAC-GGGG-ACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
37. BH12	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-TACGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
38. BH132	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
39. BH135	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
40. BH134	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
41. SP13	TGTTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
42. BH13.1	AAAATTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
43. SP13	ATGTAACGCGT-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
44. SP14	TGTTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
45. BH142	CAATTACCGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
46. BH14.1	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
47. BP14	AGTAAACCGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
48. BH15.2	AGTAAACCGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
49. SP15	AGTAAACCGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
50. BP15	ATGTAACGCGT-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
51. SP16	ATGTAACGCGT-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
52. BH16.2	NAATATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
53. BH16.1	BATGTTAA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
54. BP16	TGTTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
55. BH17.1	AAATTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
56. BH17.2	AAATTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
57. SP17	TGTTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
58. BP17	ATGTAACGCGT-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
59. BH18.1	AAATTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
60. BH19.1	AAATTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
61. BH19.2	TGTTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
62. BH20.1	ANNNTAAACCGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
63. SP20	TNTTTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
64. BH20.3	AGTTAACCGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
65. BP20	AAAGTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
66. BH21.1	AAAGTATA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC
67. SP21	GGGGCG-TTTTA-CGGTG-CGAC-GGGGG-AGGT-TCCGTGTT-CAGTGCGG-CACATTG-ACCACGCCS-AACACC-TCAAGGCCATG-ACATGC

B. PRIMER TTC



LAMPIRAN 5 POLA PENGULANGAN TTC

POLA PENGULANGAN TTC KABUPATEN MUNA											
Rumah	P/H	N/S	TTC13	TTC14	TTC15	TTC22	TTC27	TTC28	A	B	C
11	P	N		1							
	S	S		1							
	H	N	1						1		2
	H	N		1							
	H	N		1							
12	H	N			1						
	P	N			1						
	S	S		1					1	1	1
13	H	N		1							
	P	N		1							
	S	S			1						
	H	N		1							
	H	N		1							
	H	N			1						
14	H	N		1							
	P	N		1							
	S	S						1			
	H	N	1						1	1	1
15	H	N			1						
	P	N			1						
	S	S					1		1	1	1
16	H	N	1								
	P	N		1							
	S	S	1								1
17	H	N		1							
	P	N		1							
	S	S	1								1
18	H	N			1						
	P	N			1						
	H	N	1								1
19	H	N			1						
	P	N			1						
	H	N	1								
20	H	N			1						
	P	N			1						
	S	S					1				
	H	N	1						1	1	1
21	H	N			1						
	P	N			1						
	S	S		1							
TOTAL	H	N		1							
	H	N	1								
	H	N			1						
PERSEN			5	31	8	1	1	1	7	7	8
									63.64	77.78	29.63

Keterangan :

- [Yellow Box] : Pola Pengulangan TTC Sampel Skin Smear
- [Green Box] : Pola Pengulangan TTC Sampel NS Kontak
- [Blue Box] : Pola Pengulangan TTC Sampel NS Pasien
- A : Rumah dengan Kontak mendapatkan Transmisi dari Luar
- B : Individu dengan Perbedaan Strain Nasal-Skin
- C : Kontak Yang mendapatkan transmisi bukan dari pasien dalam rumah

POLA PENGULANGAN TTC KOTA KENDARI

Rumah	P/H	N/S	TTC12	TTC13	TTC14	A	B	C	
1	P	N			1				
		S			1				
		H	N	1		1		1	
2	P	N			1				
		S							
		H	N		1				
3	P	N			1				
		S			1				
		H	N	1		1		1	
4	P	N			1				
		S							
		H	N						
5	P	N		1					
		S		1					
		H	N						
6	P	N		1					
		S			1				
		H	N				1		
7	P	N			1				
		S		1					
		H	N	1			1		
8	P	N		1					
		S			1				
		H	N		1		1		
9	P	N		1					
		S			1				
		H	N				1		
10	P	N			1				
		S	1						
		H	N	1		1		1	
TOTAL		3	8	13	3	5	3		
PERSEN					50	62.50	50		

Keterangan :

	:	Pola Pengulangan TTC Sampel Skin Smear
	:	Pola Pengulangan TTC Sampel NS Kontak
	:	Pola Pengulangan TTC Sampel NS Pasien
A	:	Rumah dengan Kontak mendapatkan Transmisi dari Luar
B	:	Individu dengan Perbedaan Strain Nasal-Skin
C	:	Kontak Yang mendapatkan transmisi bukan dari pasien dalam rumah



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
PROGRAM STUDI DOKTOR ILMU KEDOKTERAN

Jl. Perintis Kemerdekaan Km. 10 Makassar 90245 Telp.(0411)586010,(0411)586297
s3kedokteranunhas@gmail.com

Nomor : 2471/UN4.6.8/PT.01.04/2024
Perihal : Permohonan Izin Penelitian

26 Februari 2024

Yth.
Kepala Balitbang
Provinsi Sulawesi Tenggara
Kendari

Dengan hormat, sehubungan dengan tugas penelitian dalam rangka penyusunan disertasi bagi mahasiswa Program Studi Doktor Ilmu Kedokteran Fakultas Kedokteran Universitas Hasanuddin dibawah ini :

Nama : **Amiruddin Eso**
Nomor Pokok : C013182002
Program Studi : Doktor Ilmu Kedokteran
Judul Penelitian :

Analisis Pola Pengulangan Sekuens Nukleotida TTC Target Gen RLEP3 X1753 Mycobacterium leprae Penderita Kusta dan Kontak Serumah Penderita Kusta di provinsi Sulawesi Tenggara.

Promotor : Dr. dr. Irfan Idris, M.Kes

Bersama ini mohon kiranya diberikan izin Melaksanakan Penelitian di Balibang Provinsi Sulawesi Tenggara. Adapun sumber dana penelitian tersebut berasal dari Biaya Mandiri. Data yang diperoleh akan dijaga kehasiaannya.

Demikian surat keterangan ini dibuat untuk dipergunakan sebagaimana mestinya.



Ketua Program Studi Doktor
Ilmu Kedokteran,

Dr. dr. Irfan Idris, M.Kes
NIP. 196711031998021001

Tembusan Yth :

1. Wakil Dekan Bidang Akademik dan Kemahasiswaan FK unhas
2. Sekretaris Program Studi Doktor Ilmu Kedokteran FK Unhas
3. Arsip



PEMERINTAH PROVINSI SULAWESI TENGGARA
BADAN RISET DAN INOVASI DAERAH

Alamat : Jl. Mayjend S. Parman No. 03 Kendari 93121
Website : <https://brida.sultra.prov.go.id> Email: bridaprovsultra@gmail.com

Kendari, 29 Februari 2024

Nomor : 070/ 742 / II /2024
Lampiran :
Perihal : Izin Penelitian

Yth. 1. Bupati Muna
2. Bupati Konawe Utara
3. Kepala Dinas Kesehatan Kota Kendari
di –
Tempat

Berdasarkan Surat Dekan Fakultas Kedokteran UNHAS Makassar Nomor : 2471/UN4.6.8/PT.01.04/2024 tanggal, 26 Februari 2024 perihal tersebut, dengan ini menerangkan bahwa Mahasiswa atas nama :

Nama : AMIRUDDIN ESO
NIM : C013182002
Prog. Studi : Doktor Ilmu Kedokteran
Pekerjaan : Mahasiswa
Lokasi Penelitian : Dinkes Kota Kendari, Dinkes Kab. Konut dan Dinkes Kab. Muna

Bermaksud untuk melakukan Penelitian/Pengambilan Data pada wilayah sesuai Lokasi penelitiannya, dalam rangka penyusunan *Disertasi*, dengan judul, "Analisis Pola Pengulangan Sekuens Nukleotida TTC Target Gen RLEP3 X1753 Mycobacterium Leprae Penderita Kusta Dan Kontak Serumah Penderita Kusta Di Provinsi Sulawesi Tenggara". Yang akan dilaksanakan dari tanggal : 29 Februari 2024 sampai selesai.

Sehubungan dengan hal tersebut, pada prinsipnya menyetujui pelaksanaan penelitian dimaksud dengan ketentuan sebagai berikut:

1. Senantiasa menjaga keamanan dan ketertiban serta mentaati perundang-undangan yang berlaku.
2. Badan Riset dan Inovasi Daerah Provinsi Sulawesi Tenggara hanya menerbitkan izin penelitian sekali untuk setiap penelitian
3. Menyerahkan 1 (satu) rangkap copy hasil penelitian kepada Gubernur Sulawesi Tenggara
Cq. Kepala Badan Riset dan Inovasi Daerah Provinsi Sulawesi Tenggara.
4. Surat izin akan dibatalkan dan dinyatakan tidak berlaku apabila di salah gunakan.

Demikian surat Izin Penelitian ini diberikan untuk digunakan sebagaimana mestinya.



Ditandatangani secara elektronik oleh:
Kepala Badan Riset dan Inovasi Daerah
Provinsi Sulawesi Tenggara
Dra. Hj. ISMA, M. Si
NIP 19660306 198603 2 016

Tembusan:

1. Gubernur Sulawesi Tenggara (sebagai laporan) di Kendari;
2. Walikota Kendari di Kendari;
3. Dekan FK UNHAS Makassar di Tempat;
4. Ketua Prodi Doktor Ilmu Kedokteran FK UNHAS Makassar di Tempat;
5. Kepala Dinas Kesehatan Kab. Muna di Tempat;
6. Kepala Dinas Kesehatan Kab. Konut di Tempat;
7. Yang Bersangkutan.-;



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET DAN TEKNOLOGI
UNIVERSITAS HALU OLEO
FAKULTAS KEDOKTERAN
KOMISI ETIK PENELITIAN KESEHATAN

Kampus Hijau Bumi Tridharma Anduonohu Jl. H.E.A. Mokodompit

Telepon (0401) 3194163, Fax (0401) 3190006, Kendari 93232 Laman: www.uho.ac.id

Surat Kelaikan Etik (*Ethical Clearance*)

Untuk Penelitian Kesehatan yang Menggunakan Manusia Sebagai Subjek Penelitian

KELAIKAN ETIK (*ETHICAL CLEARANCE*)

Nomor: 016 /UN29.17.1.3/ETIK/2024

Yang bertanda tangan di bawah ini, Ketua Komisi Etik Penelitian Kesehatan Fakultas Kedokteran Universitas Halu Oleo, setelah dilaksanakan pembahasan dan penilaian, dengan ini memutuskan protokol penelitian yang berjudul:

“ANALISIS POLA PENGULANGAN SEKUENS NUKLEOTIDA TTC TARGET GEN RLEP3 X17153 Mycobacterium leprae PENDERITA KUSTA DAN KONTAK SERUMAH PENDERITA KUSTA DI PROVINSI SULAWESI TENGGARA”

yang mengikut sertakan manusia sebagai subjek penelitian, dengan:

Ketua Pelaksana/Peneliti Utama : Amiruddin Eso

Unit/Lembaga : Universitas Hasanuddin

Tempat Penelitian : Provinsi Sulawesi Tenggara

Persetujuan ini berlaku sejak tanggal ditetapkan sampai dengan batas waktu pelaksanaan penelitian seperti tertera dalam protokol.

Pada akhir penelitian, laporan pelaksanaan penelitian harus diserahkan kepada KEP-FK UHO. Jika ada perubahan protokol dan/atau perpanjangan penelitian, harus mengajukan kembali permohonan kajian etik penelitian (amandemen protokol).

Kendari, 08 Januari 2024

Ketua Komisi Etik Penelitian,



Dr. Adius Kusnan, S.Kep., Ns., M.Kes
NIP. 19731224 199403 1 008